Press Release July 09, 2020

Kymera Therapeutics and Sanofi Enter Into $150 Million Upfront, Up-to-$2 Billion Strategic Partnership to Advance Novel Protein Degrader Therapies To Patients

The Life Sciences team advised Kymera Therapeutics Inc. on its multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program.

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins.

Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant royalty payments. Kymera retains the option to participate in U.S. development and commercialization for both programs.This includes the ability to participate equally in the costs, profits and losses after opt-in, and to co-promote partnered products in the U.S.

The Goodwin team was led by Sarah Solomon, Kathleen Kean, Sarah Stoiber, Paul Jin, and Bill Collins, with invaluable assistance from Dan Karelitz and Jonathan LaPlante

For more details, read the press release and articles in The Boston Globe, Endpoints, and FierceBiotech.